MARC보기
LDR02237nam u200457 4500
001000000418189
00520190215162645
008181129s2017 |||||||||||||||||c||eng d
020 ▼a 9780355595222
035 ▼a (MiAaPQ)AAI10638769
035 ▼a (MiAaPQ)washington:17993
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 247004
0820 ▼a 616.99
1001 ▼a Vandeven, Natalie A.
24510 ▼a Merkel Cell Carcinoma: Immunogenicity and the Characterization of CD4 T Cell Responses to the Merkel Cell Polyomavirus.
260 ▼a [S.l.]: ▼b University of Washington., ▼c 2017.
260 1 ▼a Ann Arbor: ▼b ProQuest Dissertations & Theses, ▼c 2017.
300 ▼a 194 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-05(E), Section: B.
500 ▼a Adviser: Paul Nghiem.
5021 ▼a Thesis (Ph.D.)--University of Washington, 2017.
506 ▼a This item is not available from ProQuest Dissertations & Theses.
520 ▼a Merkel cell carcinoma (MCC) is a deadly, virus-associated skin cancer with a 5-year relative mortality rate of 46%. The Merkel cell polyomavirus (MCPyV) is clonally integrated into 80% of MCCs and persistent expression of MCPyV T-antigen oncopro
520 ▼a Within the opening chapters, we explore pathogen-driven cancers more broadly (Chapter 1) before delving specifically into MCPyV-induced MCC, its rising incidence rate (Chapter 2) and known mechanisms of immune evasion (Chapter 3). Previous studi
520 ▼a This past year (2017) historically marked the first FDA approval of an agent for the treatment of advanced MCC. Therefore, as we continue to treat more MCC patients with this agent (avelumab
590 ▼a School code: 0250.
650 4 ▼a Oncology.
650 4 ▼a Immunology.
650 4 ▼a Pathology.
690 ▼a 0992
690 ▼a 0982
690 ▼a 0571
71020 ▼a University of Washington. ▼b Pathology.
7730 ▼t Dissertation Abstracts International ▼g 79-05B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0250
791 ▼a Ph.D.
792 ▼a 2017
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T14996677 ▼n KERIS ▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다.
980 ▼a 201812 ▼f 2019
990 ▼a ***1012033